HCC70 Cells

Categories: Breast cancer cell lines Description: The HCC70 cell line is derived from a triple-negative breast cancer (TNBC), a subtype that lacks expression of estrogen, progesterone, and HER2 receptors, making it difficult to treat due to limited targeted therapies. HCC70 cells are notable for their basal-like 1 (BL1) classification within TNBC subtypes, which impacts their response to chemotherapy and treatment strategies. Importantly, HCC70 cells express the G-protein-coupled estrogen receptor GPR30 at significant levels. GPR30 has been associated with rapid signaling responses to estrogens like 17beta-estradiol, influencing cell proliferation and other oncogenic pathways. A key genetic characteristic of HCC70 is the presence of a TP53 mutation, specifically the R248Q variant. This mutation is associated with gain-of-function (GOF) phenotypes that contribute to cancer cell survival and aggressive behavior. In studies, R248Q mutation in HCC70 cells has been linked to enhanced cell deformability and altered PARP1 localization, implying potential sensitivity to PARP inhibitors. Research into drug responses in HCC70 and similar TNBC cell lines has highlighted the efficacy of proteasome inhibitors and platinum-based therapies. These treatments have shown promise, with drugs like bortezomib demonstrating cytotoxic effects. The interplay between chemotherapeutic resistance and specific receptor signaling, such as that mediated by GPR30, underscores the complexity of targeting TNBC subtypes like those modeled by HCC70. Organism: Human Tissue: Mammary gland Disease: Breast ductal carcinoma Synonyms: HCC-70, HCC 70, HCC0070, Hamon Cancer Center 70 Age: 49 years Gender: Female Ethnicity: African American Morphology: Epithelial-like Cell Type: Epithelial cell Growth Properties: Adherent Citation: HCC70 (Cytion catalog number 305464) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_1270 Protein Expression: epithelial glycoprotein 2 (EGP2), cytokeratin 19 Oncogenes: her2/neu-, p53+ (overexpressed) Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% FBS Dissociation Reagent: Accutase Fluid Renewal: 2 to 3 times per week Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0